Grifols (GRFS) Gains from Sales and Divestitures (2009 - 2021)
Grifols (GRFS) posted Gains from Sales and Divestitures of $1.4 million for Q4 2021, up 7.55% quarter-over-quarter from $1.3 million in Q4 2020, and up 7.55% year-on-year from $1.3 million in Q4 2020.
Grifols (GRFS) Gains from Sales and Divestitures (2009 - 2021) Analysis & Trends
Grifols (GRFS) has reported Gains from Sales and Divestitures for 9 consecutive years, with $1.4 million the latest figure, recorded in Q4 2021.
- Gains from Sales and Divestitures for Q4 2021 came in at $1.4 million, up 7.55% year-over-year; the trailing twelve-month figure through Dec 2021 was $1.4 million (up 7.55% YoY), and the FY2021 annual result was $1.4 million, up 12.31% from the prior year.
- Gains from Sales and Divestitures was $1.4 million for Q4 2021 at Grifols, up from $1.3 million in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $1.5 million in Q4 2019 and troughed at $1.3 million in Q4 2020.
- Average Gains from Sales and Divestitures over 3 years is $1.4 million, with a median of $1.4 million recorded in 2021.
- Year-over-year, Gains from Sales and Divestitures declined 17.85% in 2020 and advanced 7.55% in 2021.
- Over 3 years, Gains from Sales and Divestitures stood at $1.5 million in 2019, then fell by 17.85% to $1.3 million in 2020, then grew by 7.55% to $1.4 million in 2021.
- Per Business Quant data, the three most recent Gains from Sales and Divestitures figures were $1.4 million in Q4 2021, $1.3 million in Q4 2020, and $1.5 million in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.37 Mn |
| Dec 31, 2021 | 1.37 Mn |
| Dec 31, 2020 | 1.27 Mn |
| Dec 31, 2020 | 1.27 Mn |
| Dec 31, 2019 | 1.55 Mn |
| Dec 31, 2019 | 1.55 Mn |
| Jun 30, 2018 | 109.47 Mn |
| Jun 30, 2018 | 109.47 Mn |
| Jun 30, 2017 | 2.00 Bn |
| Jun 30, 2017 | 2.00 Bn |
| Dec 31, 2016 | -3,225.14 |
| Dec 31, 2016 | -3,225.14 |
| Sep 30, 2016 | 91.16 Mn |
| Sep 30, 2016 | 91.16 Mn |
| Jun 30, 2016 | 924,237.77 |
| Jun 30, 2016 | 924,237.77 |
| Dec 31, 2015 | 7,367.00 |
| Dec 31, 2015 | 7,367.00 |
| Sep 30, 2015 | 86.06 Mn |
| Sep 30, 2015 | 86.06 Mn |